title: Intravitreal bevacizumab for choroidal neovascularization secondary to laser photocoagulation for central serous chorioretinopathy.
abstract: OBJECTIVE
  Choroidal neovascularization (CNV) is a rare complication after laser photocoagulation for disorders such as central serous chorioretinopathy (CSC).
  
  
  METHODS
  We report 2 patients who developed CNV after laser treatment for persistent CSC and were treated by 3 1.25-mg intravitreal injections of bevacizumab in 1-month intervals.
  
  
  RESULTS
  In both patients, best-corrected visual acuity improved from 20/120 to 20/80 and from counting fingers at 3 feet to 20/100 over 12 months of follow-up.
  
  
  CONCLUSIONS
  The favorable outcome suggests that intravitreal injection of bevacizumab may be beneficial for patients who develop CNV after laser photocoagulation. The favorable outcome may be related to the limited pathology.
authors.affiliation: Department of Ophthalmology, Ziv Medical Center, Safed, Israel.
authors.forename: Joseph
authors.initials: J
authors.lastname: Pikkel
authors.forename: Shimon
authors.initials: S
authors.lastname: Rumelt
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000601:surgery*; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000009:adverse effects*; D008297:Male; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab